Hematopoietic stem cell transplantation for HIV cure

J Clin Invest. 2016 Feb;126(2):432-7. doi: 10.1172/JCI80563. Epub 2016 Jan 5.


The apparent cure of an HIV-infected person following hematopoietic stem cell transplantation (HSCT) from an allogeneic donor homozygous for the ccr5Δ32 mutation has stimulated the search for strategies to eradicate HIV or to induce long-term remission without requiring ongoing antiretroviral therapy. A variety of approaches, including allogeneic HSCT from CCR5-deficient donors and autologous transplantation of genetically modified hematopoietic stem cells, are currently under investigation. This Review covers the experience with HSCT in HIV infection to date and provides a survey of ongoing work in the field. The challenges of developing HSCT for HIV cure in the context of safe, effective, and convenient once-daily antiretroviral therapy are also discussed.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Allografts
  • Autografts
  • HIV Infections* / genetics
  • HIV Infections* / immunology
  • HIV Infections* / therapy
  • HIV-1 / immunology*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Mutation*
  • Receptors, CCR5* / genetics
  • Receptors, CCR5* / immunology


  • CCR5 protein, human
  • Receptors, CCR5